INmune Bio (INMB) Q4 2024 Earnings Call March 27, 2025 04:30 PM ET Company Participants David Moss - Chief Financial OfficerRaymond Tesi - CEO & ChairmanGeorge Farmer - Managing DirectorMark Lowdell - Chief Scientific Officer & Chief Manufacturing OfficerCJ Barnum - Head of NeuroscienceDenis Reznik - Senior Equity Research AssociateElemer Piros - Senior Managing Director Conference Call Participants Thomas Shrader - Equity Research AnalystJames Molloy - Managing Director, Senior Biotechnology & Specialty Ph ...

INmune Bio Inc. (INMB) Q4 2024 Earnings Conference Call March 27, 2025 04:30 PM ET Company Participants Margo - Conference OperatorDavid Moss - Chief Financial Officer, ImmuneBioDr. RJ Tessie - CEO and Co-founder, ImmuneBioDr. CJ Barnum - Clinical Executive, ImmuneBioDr. Mark Liddell - Clinical Executive, ImmuneBioModerator - Call ModeratorCall Facilitator - Investor Relations Facilitator Conference Call Participants George Farmer - Analyst, ScotiabankTom Schrader - Analyst, BTIGDennis Resnick - Analyst (su ...

FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number: 001-38793 INMUNE BIO INC. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Nevada 47-5205835 (State or other jurisdiction of inco ...

Core Insights - INmune Bio Inc. reported its financial results for the year ended December 31, 2024, and provided a business update, highlighting advancements in its clinical programs and financial performance [1][9]. Financial Performance - The net loss attributable to common stockholders for 2024 was approximately $42.1 million, compared to a loss of approximately $30.0 million in 2023 [9][25]. - Research and development expenses totaled approximately $33.2 million for 2024, up from approximately $20.3 million in 2023 [9][25]. - General and administrative expenses were approximately $9.5 million for 2024, slightly down from approximately $9.6 million in 2023 [9][25]. - The company had cash and cash equivalents of approximately $20.9 million as of December 31, 2024 [9][25]. Clinical Developments - The company completed enrollment for its Phase 2 trial (AD02 trial) focused on Early Alzheimer's Disease, exceeding the target enrollment with 208 patients [4]. - Interim analyses of the AD02 trial data showed a significant correlation (p<0.001) between baseline scores on the EMACC cognitive measure and the Clinical Dementia Rating-Sum of Boxes (CDR-SB) [4]. - The EMACC measure demonstrated high reliability with a correlation of 0.93 between screening and first study visit scores [4]. - CORDStrom™ received FDA's Rare Pediatric Disease Designation and Orphan Drug Designation for treating epidermolysis bullosa [4][7]. Product Platforms - XPro™ is a next-generation TNF inhibitor in clinical trials, targeting neuroinflammation to potentially improve cognitive function in neurological diseases [11]. - CORDStrom™ is a cell medicine platform utilizing human umbilical cord-derived mesenchymal stromal cells, showing promise for treating complex inflammatory diseases [14][15]. - INKmune® is designed to prime a patient's NK cells for cancer treatment, currently in a Phase I/II trial for metastatic castration-resistant prostate cancer [16][17]. Upcoming Milestones - Top-line cognitive results from the AD02 trial are expected in June 2025 [13]. - A Phase II trial of XPro™ for Treatment-Resistant Depression will begin enrollment soon [13]. - The company anticipates filing a Biologics License Application (BLA) for CORDStrom™ in 2025 or early 2026 [13].

Boca Raton, Florida, March 24, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it will host a conference call on Thursday, March 27, 2025, at 4:30pm EDT to discuss results for its quarter ended December 31, 2024, and to provide a corporate update. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio Third Q ...

INmune Bio (NASDAQ: INMB ) has recently announced that it will be seeking approval of CORDStrom for the treatment of recessive dystrophic epidermolysis bullosa [RDEB] after favorable investigator-initiated trial results. CORDStrom was out of focus of investors. The FDA recentlyI am a long-term investor focused on growth markets, AI and biotech opportunities in my more volatile portfolio. I try to look for undervalued and under-the-radar stocks with serious potential and good scientific or other background. ...

Medical review of Phase 1 cohorts demonstrated no safety issuesData to be presented at the 10th Annual Innate Killer Summit, March 3-5 BOCA RATON, Fla, Feb. 12, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, continues to advance its Natural Killer (NK) cell therapy, INKmune™, in a Phase I/II trial (the “CaRe PC” trial) for men with metastatic castration-resistant prostate cancer (mCRPC). The Company is pleased to announce compl ...

INmune Bio (INMB) Update / Briefing February 11, 2025 11:08 AM ET Company Participants Mark Lowdell - Chief Scientific Officer & Chief Manufacturing OfficerAnna Elizabeth Martinez - Consultant - Paediatric DermatologyGeorge Farmer - Managing DirectorGary Nachman - Managing Director - Equity ResearchElemer Piros - Senior Managing DirectorJason Mccarthy - Senior Managing Director Conference Call Participants Joel Beatty - Senior Research Analyst Operator Good morning, and welcome to the Immune Bio Investor Ev ...

The Company reports results of a double-blinded, randomized, placebo-controlled study, known as "MissionEB," investigating CORDStrom for treatment of RDEB in pediatric patients, which evidence a favorable benefit-risk profile in support of the intended applications for marketing authorization. CORDStrom, developed by INmune Bio is a patent pending, off the shelf, advanced mesenchymal stromal cell (MSC) platform developed to treat complex inflammatory diseases that has significant clinical development advant ...

First patient treated in Phase II portion of clinical trial in metastatic prostate cancer at the West Los Angeles Veterans Administration Hospital Boca Raton, Florida, Jan. 28, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, has an ongoing Phase I/II trial in men with metastatic castration-resistant prostate cancer (mCRPC). The Comp ...